Over the last decade, the APJ receptor has received ongoing interest as an attractive therapeutic target for the treatment of heart failure and cardiovascular diseases, notably due to its inodilator properties following activation, causing marked arterial vasodilation and positive inotropic effect (Tatemoto et al., 1998; Szokodi et al., 2002; Coquerel et al., 2018). Here, APLNR is linked to cardiovascular disorder.